{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:37Z","timestamp":1793234317954,"version":"4.5.0"},"reference-count":111,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Infections are well known complications of some targeted drugs used to treat solid organ cancer and hematological malignancies. Furthermore, Individual patient risk factors are associated with underlying pathologies, concomitant immunosuppressive treatment, prior treatment and use of anti-infective prophylaxis. Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Objectives: In this narrative review, we present the current state of knowledge concerning the infectious complications occurring in patients treated with immune checkpoint inhibitors (ICIs), Bruton\u2019s tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, antiapoptotic protein BCL-2 inhibitors, Janus kinase inhibitors or CAR-T cell infusion. Sources: We searched for studies treating infectious complications of ICIs, BTK inhibitors, PI3K inhibitors, antiapoptotic protein BCL-2 inhibitors and CAR-T cell therapy. We included randomized, observational studies and case reports. Content: Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Treatment of irAEs with corticosteroids and other immunosuppressive agents can lead to opportunistic infections. Bruton\u2019s tyrosine kinase (BTK) inhibitors are associated with higher rate of infections, including invasive fungal infections. Implications:\u00a0Infections, particularly fungal ones, are common in patients treated with BTK inhibitors even though most of the complications occurring among patients treated by ICIs or CART-cells infusion are associated with the treatment of side effects related to the use of these new treatments. The diagnosis of these infectious complications can be difficult and may require extensive investigations.<\/jats:p>","DOI":"10.3390\/cancers15071989","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:18:27Z","timestamp":1679883507000},"page":"1989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias\/Lymphomas"],"prefix":"10.3390","volume":"15","author":[{"given":"Beno\u00eet","family":"Pilmis","sequence":"first","affiliation":[{"name":"Equipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 75014 Paris, France"},{"name":"UMR 1319, Institut Micalis, Universit\u00e9 Paris-Saclay, INRAeCh\u00e2tenay Malabry, AgroParisTech, 92290 Chatenay Malabry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Kherabi","sequence":"additional","affiliation":[{"name":"Equipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Huriez","sequence":"additional","affiliation":[{"name":"Equipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[{"name":"Infection Control Unit, AP-HP H\u00f4pital Avicenne, Universit\u00e9 Sorbonne Paris Nord, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamel","family":"Mokart","sequence":"additional","affiliation":[{"name":"Medical Surgical Intensive Care Unit, Institut Paoli Calmettes, 13009 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13613-021-00968-5","article-title":"Patterns of ICU Admissions and Outcomes in Patients with Solid Malignancies over the Revolution of Cancer Treatment","volume":"11","author":"Vigneron","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and Safety of Ipilimumab Monotherapy in Patients with Pretreated Advanced Melanoma: A Multicenter Single-Arm Phase II Study","volume":"21","author":"Maio","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus Ipilimumab or Nivolumab Alone versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-Year Outcomes of a Multicentre, Randomised, Phase 3 Trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus of atumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended Treatment with Single-Agent Ibrutinib at the 420 Mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"23","author":"Furman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-Year Follow-up of Treatment-Na\u00efve and Previously Treated Patients with CLL and SLL Receiving Single-Agent Ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma: Extended 3.5-Year Follow up from a Pooled Analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled Safety Analysis of Zanubrutinib Monotherapy in Patients with B-Cell Malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/14740338.2020.1826435","article-title":"The Safety of Available Chemo-Free Treatments for Mantle Cell Lymphoma","volume":"19","author":"Robak","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_11","first-page":"20406207221101696","article-title":"The Potential of Pirtobrutinib in Multiple B-Cell Malignancies","volume":"13","author":"Jensen","year":"2022","journal-title":"Adv. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-Human Phase 1 Study of the BTK Inhibitor GDC-0853 in Relapsed or Refractory B-Cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"key":"ref_13","first-page":"604","article-title":"Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice","volume":"7","author":"Driscoll","year":"2016","journal-title":"J. Adv. Pr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of Adverse Events Associated with Idelalisib Treatment in Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Multidisciplinary Position Paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.17475","article-title":"A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients with Chronic Lymphocytic Leukaemia Treated with Idelalisib and Rituximab in the UK and Ireland (RETRO-Idel)","volume":"194","author":"Eyre","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine\/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am J Hematol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","article-title":"Safety and Efficacy of Dual PI3K-\u03b4, \u03b3 Inhibitor, Duvelisib in Patients with Relapsed or Refractory Lymphoid Neoplasms: A Systematic Review and Meta-Analysis of Prospective Clinical Trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00701","DOI":"10.14309\/crj.0000000000000701","article-title":"Umbralisib-Induced Immune-Mediated Colitis: A Concerning Adverse Effect of the Novel PI3K\u03b4\/CK1\u03b5 Inhibitor","volume":"8","author":"Bajaj","year":"2021","journal-title":"ACG Case Rep. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A Phase 1\/2 Trial of Ublituximab, a Novel Anti-CD20 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia Previously Exposed to Rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse Events Associated with JAK Inhibitors in 126,815 Reports from the WHO Pharmacovigilance Database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and MTOR Inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor Immunotherapies by Immune Checkpoint Inhibitors (ICIs); the Pros and Cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus Chemotherapy in Patients with Advanced Melanoma Who Progressed after Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 Blockade Expands Intratumoral Memory T Cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1086\/599039","article-title":"Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry","volume":"48","author":"Horn","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Groupe de Recherche en Reanimation Respiratoire du patient d\u2019Onco-H\u00e9matologie (Grrr-OH) Severe Toxicity from Checkpoint Protein Inhibitors: What Intensive Care Physicians Need to Know?","volume":"9","author":"Lemiale","year":"2019","journal-title":"Ann. Intensive Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cam4.4393","article-title":"Infectious Complications of Immune Checkpoint Inhibitors in Solid Organ Malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma","volume":"63","author":"Romero","year":"2016","journal-title":"Clin. Infect Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11046-018-0291-4","article-title":"Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas Aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature","volume":"184","author":"Oltolini","year":"2019","journal-title":"Mycopathologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/1759-7714.13422","article-title":"Opportunistic Infections Complicating Immunotherapy for Non-Small Cell Lung Cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00580","DOI":"10.1002\/rcr2.580","article-title":"Destroyed Lung Due to Sustained Inflammation after Chemoradiotherapy Followed by Durvalumab","volume":"8","author":"Taima","year":"2020","journal-title":"Respirol. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic Infections in Patients Treated with Immunotherapy for Cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","first-page":"2178925","article-title":"Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab","volume":"2019","author":"Gupta","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jinf.2019.10.022","article-title":"Necrotizing Soft Tissue Invasive Aspergillosis in a Cancer Patient Treated with Immunosupressants Due to Checkpoint Inhibitor-Induced Hepatitis","volume":"80","author":"Malek","year":"2020","journal-title":"J. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1040218","DOI":"10.1080\/2162402X.2015.1040218","article-title":"Immunosuppression for Ipilimumab-Related Toxicity Can Cause Pneumocystis Pneumonia but Spare Antitumor Immune Control","volume":"4","author":"Arriola","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2018.12.006","article-title":"Immunosuppression for Immune Checkpoint-Related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-Small-Cell Lung Cancer (NSCLC): A Report of 2 Cases","volume":"20","author":"Schwarz","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/MPH.0000000000001757","article-title":"An Usual Presentation of Pneumocystis Jirovecii Pneumonia in a Woman Treated With Immune Checkpoint Inhibitor","volume":"43","author":"Si","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/ejh.13751","article-title":"Progressive Multifocal Leukoencephalopathy in the Context of Newer Therapies in Hematology and Review of New Treatment Strategies","volume":"108","author":"Diamantopoulos","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1111\/ene.15021","article-title":"Immune Checkpoint Inhibitors for Progressive Multifocal Leukoencephalopathy: Identifying Relevant Outcome Factors","volume":"28","author":"Lambert","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2408.180460","article-title":"Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab","volume":"24","author":"Martinot","year":"2018","journal-title":"Emerg. Infect Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000506186","article-title":"Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis","volume":"14","author":"Furuta","year":"2020","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2018.12.027","article-title":"CMV Disease and Colitis in a Kidney Transplanted Patient under Pembrolizumab","volume":"109","author":"Gueguen","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e000577","DOI":"10.1136\/jitc-2020-000577","article-title":"Campylobacteriosis Following Immunosuppression for Immune Checkpoint Inhibitor-Related Toxicity","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of Toxicities of Immune Checkpoint Inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and Treatment of Cancer-Related Infections","volume":"10","author":"Baden","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40265-018-1003-6","article-title":"Targeting Bruton\u2019s Tyrosine Kinase Across B-Cell Malignancies","volume":"78","author":"Niemann","year":"2018","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic Review of Infectious Events with the Bruton Tyrosine Kinase Inhibitor Ibrutinib in the Treatment of Hematologic Malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1002\/cam4.4293","article-title":"Severe Infections in Patients with Lymphoproliferative Diseases Treated with New Targeted Drugs: A Multicentric Real-world Study","volume":"10","author":"Carpio","year":"2021","journal-title":"Cancer Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin. Infect Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12281-019-00343-9","article-title":"Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors","volume":"13","author":"Zarakas","year":"2019","journal-title":"Curr. Fungal. Infect Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1080\/10428194.2018.1543884","article-title":"High Rates of Proven Invasive Fungal Disease with the Use of Ibrutinib Monotherapy for Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"60","author":"Teh","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/myc.13120","article-title":"Non-Aspergillus Invasive Mould Infections in Patients Treated with Ibrutinib","volume":"63","author":"Anastasopoulou","year":"2020","journal-title":"Mycoses"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"ofw261","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib","volume":"4","author":"Messina","year":"2017","journal-title":"Open Forum. Infect Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/1078155217752078","article-title":"Cryptococcal Infections in Two Patients Receiving Ibrutinib Therapy for Chronic Lymphocytic Leukemia","volume":"25","author":"Stankowicz","year":"2019","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral Infection\/Reactivation during Long-Term Follow-up in Multiple Myeloma Patients with Anti-BCMA CAR Therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal Infections in Patients Treated with Ibrutinib: Two Unusual Cases of Invasive Aspergillosis and Cryptococcal Meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib Blocks Btk-Dependent NF-\u0138B and NFAT Responses in Human Macrophages during Aspergillus Fumigatus Phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin. Infect Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib May Impair Serological Responses to Influenza Vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of Adverse Events Associated with Idelalisib Treatment: Expert Panel Opinion","volume":"56","author":"Barrientos","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the Management of Lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e234113","DOI":"10.1136\/bcr-2019-234113","article-title":"Opportunistic Coinfection with Pneumocystis Jirovecii and Coccidioides Immitis Associated with Idelalisib Treatment in a Patient with Chronic Lymphocytic Leukaemia","volume":"13","author":"Ward","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and Preliminary Efficacy of Venetoclax with Decitabine or Azacitidine in Elderly Patients with Previously Untreated Acute Myeloid Leukaemia: A Non-Randomised, Open-Label, Phase 1b Study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the Treatment of Inadequately Controlled Polycythaemia Vera without Splenomegaly (RESPONSE-2): A Randomised, Open-Label, Phase 3b Study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A Systematic Review and Meta-Analysis of Infection Risk with Small Molecule JAK Inhibitors in Rheumatoid Arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and Efficacy of Tofacitinib for up to 9.5\u2009Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive Cell Transfer: A Clinical Path to Effective Cancer Immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving Gene-Engineered T Cell Immunotherapy of Cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-Cell Cancer with T Cells Expressing Anti-CD19 Chimeric Antigen Receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical Utilization of Chimeric Antigen Receptor T-Cells (CAR-T) in B-Cell Acute Lymphoblastic Leukemia (ALL)-an Expert Opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and Risk Factors of Infections Following CD28-Based CD19 CAR-T Cells","volume":"62","author":"Sherman","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients with Refractory Large B Cell Lymphoma Including Two with HIV and Viral Hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune Reconstitution and Associated Infections Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune Reconstitution and Infectious Complications Following Axicabtagene Ciloleucel Therapy for Large B-Cell Lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/10428194.2021.2010062","article-title":"Incidence and Prophylaxis of Herpes Zoster in Relapsed or Refractory B-Cell Lymphoma Patients after CD19-Specific CAR-T Cell Therapy","volume":"63","author":"Liu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CJI.0000000000000388","article-title":"CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-Modified T (CAR-T)-Cell Immunotherapy","volume":"44","author":"Heldman","year":"2021","journal-title":"J. Immunother"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin. Infect Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2020.2367","article-title":"Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment","volume":"6","author":"Abid","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results of a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T Cells: A Report on Current Challenges and Future Directions from the EPICOVIDEHA Survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Rejeski, K., Kunz, W.G., Rudelius, M., B\u00fccklein, V., Blumenberg, V., Schmidt, C., Karschnia, P., Sch\u00f6berl, F., Dimitriadis, K., and von Baumgarten, L. (2021). Severe Candida Glabrata Pancolitis and Fatal Aspergillus Fumigatus Pulmonary Infection in the Setting of Bone Marrow Aplasia after CD19-Directed CAR T-Cell Therapy\u2014A Case Report. BMC Infect Dis., 21.","DOI":"10.1186\/s12879-020-05755-4"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious Complications of CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: Timeline, Prevention, and Uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr. Opin. Infect Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of Adults and Children Undergoing Chimeric Antigen Receptor T-Cell Therapy: Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for Screening, Monitoring, Prevention, and Prophylaxis of Infections in Adult and Pediatric Patients Receiving CAR T-Cell Therapy: A Position Paper","volume":"49","author":"Iacoboni","year":"2021","journal-title":"Infection"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-Effect Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF Does Not Worsen Toxicities and Efficacy of CAR-T Cells in Refractory\/Relapsed B-Cell Lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of Patients with Haematological Malignancies Who Did Not Have Transplantations: Guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/1989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:39Z","timestamp":1760123019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/1989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":111,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15071989"],"URL":"https:\/\/doi.org\/10.3390\/cancers15071989","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}